PH awaits Bharat Biotech docs for Covaxin delivery

The Philippines awaits the submission of regulatory requirements from Indian manufacturer Bharat Biotech before the delivery of its COVID-19 vaccine, Covaxin.

Philippine Ambassador to India Ramon Bagatsing Jr. urged Philippine regulatory authorities to expedite these requirements.

The Philippine FDA requires one specific document from Bharat Biotech for the full approval of Covaxin.

The Department of Finance is also reviewing the pricing scheme of Covaxin and needs documents from the manufacturer.

The country has secured 8 million doses of Covaxin, which has an efficacy rate of 78% and has already received emergency use authorization.

Additionally, 30 million doses of Novavax's vaccine, Covavax, manufactured by India's Serum Institute, are expected to be shipped by September, pending FDA emergency use authorization.

Topics in this story

Explore more stories about these topics.

🤖

This story was generated by AI to help you understand the key points. For more detailed coverage, please see the news articles from trusted media outlets below.

News Sources

See how different news organizations are covering this story. Below are the original articles from various Philippine news sources that contributed to this summary.